A randomized controlled trial of Structural Ecosystems Therapy for HIV medication adherence and substance abuse relapse prevention

Drug and Alcohol Dependence

Volumn 111, Issue 3, 2010, Pages 227-234

  Feaster, Daniel J ^a   Mitrani, Victoria B ^b   Burns, Myron J ^c   McCabe, Brian E ^b   Brincks, Ahnalee M ^a   Rodriguez, Allan E ^a   Asthana, Deshratn ^a   Robbins, Michael S ^d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c NEVADA STATE COLLEGE   (United States)

^d OREGON RESEARCH INSTITUTE   (United States)

Author keywords

Family therapy; HIV infection; Minority women; Relapse

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG USE; FAMILY THERAPY; FEMALE; HEALTH CARE UTILIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVENTION STUDY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOEDUCATION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; STRUCTURAL ECOSYSTEMS THERAPY; SUBSTANCE ABUSE;

ADULT; ANTI-HIV AGENTS; ECOSYSTEM; FEMALE; FOLLOW-UP STUDIES; HIV SEROPOSITIVITY; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; PILOT PROJECTS; RECURRENCE; SUBSTANCE-RELATED DISORDERS;

EID: 77957295353     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.04.017     Document Type: Article

References (54)

1. Atkins D.C., Gallop R.J. Rethinking how family researchers model infrequent outcomes: a tutorial on count regression and zero-inflated models. Journal of Family Psychology 2007, 21:726-735.
2. Baker S.A., Beadnell B., Stoner S., Morrison D.M., Gordon J., Collier C., Knox K., Wickizer L., Stielstra S. Skills training versus health education to prevent STDs/HIV in heterosexual women: a randomized controlled trial utilizing biological outcomes. AIDS Education and Prevention 2003, 15(1):1-14.
3. Bangsberg D.R. Less than 95% adherence to nonnucleoside reverse transcriptase inhibitor therapy can lead to viral suppression. Clinical Infectious Diseases 2006, 43:939-941.
4. Bogart L.M., Kelly J.A., Catz S.L., Sosman J.M. Impact of medical and non-medical factors on physician decision making for HIV/AIDS antiretroviral treatment. Journal of Acquired Immunodeficiency Syndromes 2000, 23:396-404.
5. Boyd-Franklin N. Black Families in Therapy 1989, Guilford Press, NY.
6. Boyd C., Holmes C. Women who smoke crack and their family substance abuse problems. Health Care for Women International 2002, 23:576-586.
7. Burns S.M., Maniss S., Young L., Gaubatz M. Attributions of control and seropositivity among Latinos: Examining the predictive utility of the locus of control construct. AIDS Care 2005, 17(2):263-269.
8. Calsyn R.J., Klinkenberg W.D., Morse G.A., Miller J., Cruthis R. Recruitment, engagement, and retention of people living with HIV and co-occurring mental health and substance use disorders. AIDS Care 2004, 16(1):56-70.
9. Center for Disease Control and Prevention, August 2008. HIV/AIDS among women. Retrieved June 15, 2009, from CDC/HIV/AIDS fact sheet: http://www.cdc.gov/hiv.
10. Center for Disease Control and Prevention 2005. HIV/AIDS Surveillance Report, vol. 17, pp. 1-46.
11. Chesney M.A., Ickovics J.R., Chambers D.B., Gifford A.L., Neidig J., Zwickl B., Wu A.W. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care 2000, 12(3):255-266.
12. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Lawrence Erlbaum Associates, Hillsdale, NJ.
13. Dennis M.L., Scott C.K., Funk R. An experimental evaluation of recovery management checkups (RMC) for people with chronic substance use disorders. Evaluation and Program Planning 2003, 26:339-352.
14. Edlin B.R., Irwin K.L., Faruque S., McCoy C.B., Word C., Serrano Y., Inciardi J.A., Bowser B.P., Schilling R.F., Holmberg S.D. Intersecting epidemics-crack cocaine use and HIV infection among inner-city young adults. New England Journal of Medicine 1994, 331:1422-1427.
15. Feaster D.J., Burns M.J., Brincks A.M., Prado G., Mitrani V.B., Mauer M.H., Szapocznik J. Structural ecosystems therapy for HIV+ African American women and drug abuse relapse. Family Process 2010, 49:204-219.
16. Feaster D.J., Brincks A.M., Mitrani V.B., Prado G., Schwartz S.J., Szapocznik J. The efficacy of structural ecosystems therapy for HIV medication adherence with African American women. Journal of Family Therapy 2010, 24:51-59.
17. García P.R., Côté J.K. Factors affecting adherence to antiretroviral therapy in people living with HIV/AIDS. Journal of the Association of Nurses in AIDS Care 2003, 14:37-45.
18. Grella C.E., Scott C.K., Foss M.A., Joshi V., Hser Y.I. Gender differences in drug treatment outcomes among participants in the Chicago Target Cities Study. Evaluation and Program Planning 2003, 26(3):297-310.
19. Hayden E.C. 'Seek, test and treat' slows HIV. Nature 2010, 463:1006. Retrieved on April 10, 2010 from http://www.nature.com/news /2010/100224/full/4631006a.html?s=news_rss. 10.1038/4631006a.
20. Hedeker D., Gibbons R.D. Longitudinal Data Analysis 2006, Wiley-Interscience, Hoboken, NJ.
21. Hedeker D., Gibbons R.D., Waternaux C. Sample size estimation for longitudinal designs with attrition: Comparing time-related contrasts between two groups. Journal of Educational and Behavioral Statistics 1999, 24:70-93.
22. Iraurgi-Castillo I., Sanz-Vazquez M., Martinez-Pampliega A. Family functioning and addiction severity in persons that request treatment. Addictions 2004, 16(3):185-195.
23. Kitahata M., Gange S., Abraham A. Effect of early versus deferred antiretroviral therapy for HIV on survival. New England Journal of Medicine 2009, 360:1815-1826.
24. Leigh B.C., Stall R. Substance use and risky sexual behavior for exposure to HIV: issues in methodology, interpretation, and prevention. American Psychologist 1993, 48:1035-1045.
25. Lucas G., Cheever L., Chaisson R., Moore R.D. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. Journal of Acquired Immune Deficiency Syndrome 2001, 27:251-259.
26. Markowitz J.C., Spielman L.A., Sullivan M., Fishman B. An exploratory study of ethnicity and psychotherapy outcome among HIV-positive patients with depressive symptoms. Journal of Psychotherapy Practice and Research 2000, 9:226-231.
27. McGahan P., Griffith J., Parente R., McLellan T. Addiction Severity Index Composite Scores Manual 1986, Treatment Research Institute, Philadelphia, PA.
28. Mertens J.R., Flisher A.J., Satre D.D., Weisner C.M. The role of medical conditions and primary care services in 5-year substance use outcomes among chemical dependency treatment patients. Drug and Alcohol Dependence 2008, 98:45-53.
29. Mitrani, V.B, Feaster, D.J., Weiss-Laxer, N.S., McCabe, B.E., (in press). Malaise, motivation and motherhood: Predictors of engagement in behavioral interventions from a randomized controlled trial for HIV+ women in drug abuse recovery. AIDS and Behavior.
30. Mitrani V.B., McCabe B.E., Feaster D.J., Weiss-Laxer N.S., Robinson C. Psychological Outcomes Among Children of HIV+ Mothers in Substance Abuse Recovery: Results of a Randomized Controlled Trial of Structural Ecosystems Therapy 2009, University of Miami.
31. Mitrani V.B., Weiss-Laxer N.S., Ow C.E., Burns M.J., Ross S., Feaster D.J. Examining family networks of HIV+ women in drug recovery: challenges and opportunities. Families, Systems, and Health 2009, 27:267-283.
32. Mitrani V.B., Prado G., Feaster D.J., Robinson-Batista C., Szapocznik J. Relational factors and family treatment engagement among low-income, HIV-positive African American mothers. Family Process 2003, 42(1):31-45.
33. Mitrani V.B., Robinson C., Szapocznik J. Structural Ecosystems Therapy (SET) for women with HIV/AIDS. Handbook of Family Psychology 2009, Blackwell Publishing. M. Stanton, J. Bray (Eds.).
34. Moos R.H. Theory-based processes that promote the remission of substance use disorders. Clinical Psychology Review 2007, 27:537-551.
35. Muthén L.K., Muthén B.O. Mplus User's Guide 1998-2007, Author, Los Angeles, CA. 5th ed.
36. National Institute on Drug Abuse, 2008. Drug abuse and the link to HIV/AIDS and other infectious diseases. Retrieved June 15, 2009, from NIDA Info Facts: http://www.drugabuse.gov/.
37. National Institute on Drug Abuse, March 2006. HIV/AIDS: How does drug abuse impact the HIV/AIDS epidemic? NIDA Research Report Series, NIH Publication Number 06-5760.
38. Parienti J., Das-Douglas M., Massari V., Guzman D., Deeks S.G., Verdon R., Bangsberg D.R. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One 2008, 3(7):e2783.
39. Prado G., Szapocznik J., Mitrani V.B., Mauer M.H., Smith L., Feaster D.J. Factors influencing engagement into interventions for adaptation to HIV in African American women. AIDS and Behavior 2002, 6:141-151.
40. Quinn T., Wawer M., Sewankambo N. Viral load and heterosexual transmission of human immunodeficiency virus type 1. New England Journal of Medicine 2003, 355:921-929. Rakai Project Study Group.
41. Remien R.H., Stirratt M.J., Dolezal C., Dognin J.S., Glenn J.W., Carballo-Dieguez A., El-Bassel N., Jung T.M. Couple-focused support to improve HIV medication adherence: a randomized controlled trial. AIDS 2005, 19:807-814.
42. Roberts C.S., Feetham S.L. Assessing family functioning across three areas of relationships. Nursing Research 1982, 31(4):231-235.
43. Scott C.K., Dennis M.L., Foss M.A. Utilizing recovery management checkups to shorten the cycle of relapse, treatment reentry, and recovery. Drug and Alcohol Dependence 2005, 78(3):325-338.
44. Sherer R. Adherence and antiretroviral therapy in injection drug users. Journal American Medical Association 1998, 280(6):567-568.
45. Smith L., Feaster D.J., Prado G., Kamin M., Blaney N., Szapocznik J. The psychosocial functioning of HIV+ HIV- African American mothers. AIDS and Behavior 2001, 5:219-231.
46. Sylla L., Bruce R.D., Kamarulzaman A., Altice F.L. Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. The International Journal of Drug Policy 2007, 18:306-312.
47. Szapocznik J., Feaster D.J., Mitrani V.B., Prado G., Smith W., Robinson-Batista C., Schwartz S.J., Mauer M.H., Robbins M.S. Structural Ecosystems Therapy for HIV-seropositive African-American women: effects on psychological distress, family hassles, and family support. Journal of Consulting and Clinical Psychology 2004, 72(2):288-303.
48. Traynor K. HIV treatment guidelines revised. American Journal of Health-System Pharmacy 2010, 67:94.
49. Turner J.G., Nokes K.M., Corless I.B., Holzemer W.L., Inouye J., Brown M.A., Powell-Cope G.M. History of drug use and adherence in HIV+ persons. International Conference AIDS, 12 1998, 595. (abstract no. 391/32366).
50. Wei L.J., Lachin J.M. Properties of the Urn randomization in clinical trials. Controlled Clinical Trials 1988, 9:345-364.
51. Williams M., Bowen A., Ross M., Freeman R., Elwood W. Perceived compliance with AZT dosing among a sample of African-American drug users. International Journal of STD & AIDS 2000, 11(1):57-63.
52. Wong M.D., Cunningham W.E., Shapiro M.F., Andersen R.M., Cleary P.D., Duan N., Liu H.H., Wilson I.B., Landon B.E., Wenger N.S. Disparities in HIV treatment and physician attitudes about delaying protease inhibitors for nonadherent patients. Journal of General Internal Medicine 2004, 19:366-374. HCSUS Consortium.
53. World Health Organization CIDI-Auto 2.1: Administrator's Guide and Reference 1997, World Health Organization, Sydney.
54. Zolopa A.R. The evolution of HIV treatment guidelines: current state-of-the-art of ART. Antiviral Research 2010, 85:241-244.